Recurrence of Optimally Treated Malignant Peritoneal Mesothelioma with Cytoreduction and Heated Intraperitoneal Chemotherapy

Abstract

Absence of gross disease at the second operation was not statistically protective against recurrence compared with presence of quantifiable residual disease (Group B) that was effectively cytoreduced. Long-term disease surveillance is recommended, because recurrence continues years after treatment. Where a question of recurrence arises on surveillance, males may benefit from a higher degree of suspicion.

Morbidity and Mortality Rates Following Cytoreductive Surgery Combined With Hyperthermic Intraperitoneal Chemotherapy Compared With Other High-Risk Surgical Oncology Procedures

“…In mesothelioma and appendix peritoneal metastasis, CRS/HIPEC has significantly improved 5-year survival from less than 10% to 50% to 90%, and CRS/HIPEC is considered the standard of care for these tumor types. 10 , 31 , 34 , 35 , 36 , 37 , 38 Data continue to emerge that support adding HIPEC to CRS surgery in ovarian cancer, with the largest series (1051 patients) receiving CRS/HIPEC reporting a median survival of 73 months. 30 Also, 2 recent phase 3 randomized clinical trials investigating CRS/HIPEC in recurrent and primary stage III ovarian cancer demonstrated that HIPEC yielded a 2-fold overall survival benefit and 11-month overall survival benefit, respectively.…”

In-Hospital Mortality and Complication Rates According to Health Insurance Data in Patients Undergoing Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Surface Malignancies in Germany

“…In the last couple of years, improvements in palliative chemotherapy and cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) were able to achieve a survival benefit for a selected subset of patients with colorectal, ovarian, appendix peritoneal metastasis, mesothelioma, and pseudomyxoma peritonei. [1][2][3][4][5][6][7][8][9][10][11][12][13][14][15][16][17] After almost 20 years of HIPEC administration, the process of selecting appropriate patients underwent an outstanding evolution. Meanwhile, there are a variety of positive and negative prognostic factors (patient, tumor, and molecular pathological features) that influence the decision-making process to reduce postoperative morbidity and mortality rates and optimize the oncological benefit.…”

Das diffuse maligne peritoneale Mesotheliom (DMPM) – eine seltene Diagnose

“…So wurden Patienten in einer Studie von Heller et al zwei bis drei Wochen nach CRS und HIPEC bei MPM wöchentlich insgesamt achtmal intraperitoneale Gaben von Cisplatin (100 mg/m 2 ) oder Cisplatin (50 mg/m 2 ) mit Gemcitabine (250 mg/m 2 ), abwechselnd mit Doxorubicin (25 mg), verabreicht. Die mediane Überlebenszeit nach der Operation war 6,65 Jahre, wobei das Erreichen einer CC ≤ 1-Situation ein signifikant positiver prädiktiver Faktor für das Überleben war [34]. Ob dieses Therapieverfahren Verankerung in Leitlinien findet, ist noch unklar.…”